Form 4: Akoya Biosciences Chief Clinical Officer Receives 40,000 Restricted Stock Units

Pascal Bamford, Chief Clinical Officer of Akoya Biosciences, acquired 40,000 restricted stock units on August 29, 2024.

Summary

• On August 29, 2024, Pascal Bamford, the Chief Clinical Officer of Akoya Biosciences, Inc., acquired 40,000 restricted stock units.
• These restricted stock units vest in full on the second anniversary of the first day of the month subsequent to the grant date.
• Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
• Following this transaction, Bamford directly owns 122,758 shares of Akoya Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of stock units by an executive is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of restricted stock units by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon continued service with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company.

Key Dates